Copyright WILEY-VCH Verlag GmbH & Co. KGaA, 69469 Weinheim, Germany, 2018.



Supporting Information

for Adv. Energy Mater., DOI: 10.1002/aenm.201703603

Donor–Acceptor–Acceptor's Molecules for Vacuum-Deposited Organic Photovoltaics with Efficiency Exceeding 9%

Xiaozhou Che, Chin-Lung Chung, Chou-Chun Hsu, Feng Liu, Ken-Tsung Wong,* and Stephen R. Forrest*

Supporting Information

Donor-Acceptor-Acceptor' Molecules for Vacuum-deposited Organic Photovoltaics with Efficiency Exceeding 9%

Xiaozhou Che[#], Chin-Lung Chung[#], Chou-Chun Hsu, Feng Liu, Ken-Tsung Wong^{*}, and Stephen R. Forrest^{*}

These authors contributed equally.

X. Che, Prof. S. R. Forrest Applied Physics Program University of Michigan Ann Arbor, MI 48109, USA E-mail: <u>stevefor@umich.edu</u>


C.-L. Chung, C.-C. Hsu, Prof. K.-T. Wong Department of Chemistry National Taiwan University Taipei, 10617, Taiwan E-mail: kenwong@ntu.edu.tw

F. Liu

Department of Physics and Astronomy, and Collaborative Innovation Center of IFSA (CICIFSA) Shanghai Jiaotong University, Shanghai 200240, P. R. China.

Prof. K.-T. Wong Institute of Atomic and Molecular Science, Academia Sinica Taipei, 10617, Taiwan

Prof. S. R. Forrest Departments of Physics, and Department of Electrical Engineering and Computer Science University of Michigan Ann Arbor, MI 48109, USA The syntheses of **nBuBTDC** and **iBuBTDC** are shown in Scheme S1. Compound **1** was cyclized by Pd-catalyzed tandem C-N bond coupling with butan-1-amine or 2-methylpropan-1-amine to afford the corresponding heterotetracene **2** and **3**, respectively. The final targeted isomers were obtained by the same synthetic protocols as those described for the synthesis of **antiBTDC**.^[1] The detail procedures and characterizations of new compounds are shown in the last part of SI.



Scheme S1. Synthetic procedures for nBuBTDC and iBuBTDC.




Figure S1. Cyclic voltammograms (CV) of **nBuBTDC** and **iBuBTDC**. It is referenced to the Ferrocenium/Ferrocene (Fc^+/Fc) redox couple, where the HOMO of Fc is assigned to be -4.8 eV relative to the vacuum level.




Figure S2. Optimization of the iBuBTDC: C_{70} cells. a)/c)External quantum efficiency (*EQE*) and b)/d) device parameter plots with different donor:acceptor ratios and active layer thicknesses. The active layer thickness of a) and b) is fixed at 40 nm; the D:A ratio of c) and d) is fixed at 1:3.




Figure S3. Atomic force microscopy (AFM) images of the three d-a-a': C_{70} blend thin films. R_q refers to the mean square roughness.




Figure S4. a) Two-dimensional grazing incidence X-ray diffraction (GIXD) scattering patterns of d-a-a':C₇₀ 1:3 blend thin films; and b) the corresponding line cut profiles.

Dye	$\lambda_{calc} (nm)^a$	HUMO/ LUMO (eV) ^b	$f^{\mathfrak{c}}$	MO composition ^c
antiBTDC	676	-5.36/-3.33	1.12	98% HOMO→LUMO
				2% HOMO−1→LUMO
iBuBTDC	676	-5 33/-3 33	1.09	98% HOMO→LUMO
		-5.55/-5.55	1.09	2% HOMO−1→LUMO
nBuBTDC	678	-5.33/-3.33	1.10	98% HOMO→LUMO
				2% HOMO−1→LUMO

Table S1. Computed lowest-energy electronic transition ($S_1 \leftarrow S_0$) parameters.

^a Calculated $S_1 \leftarrow S_0$ transition energy levels.

^bOscillator strengths.

^c Molecular orbital (MO) compositions in terms of the corresponding contribution.

Dye	λ _{max} (nm)	$\lambda_{\text{onset, film}}$ (nm)	ΔE_{opt} (eV) ^c	HOMO (eV) ^d	LUMO (eV) ^e	ΔE_{CV} (eV) ^g	T _d (°C) ^h
antiBTDC	612 ^a	815	1.52	-5.40	-3.88	1.52	331
iBuBTDC	630 ^b	809	1.53	-5.35 ^f	-3.83 ^f	1.52	339
nBuBTDC	630 ^b	809	1.53	-5.35 ^f	- 3.83 ^f	1.52	341

Table S2. Physical parameters of antiBTDC, iBuBTDC and nBuBTDC.

^a Measured in CH₂Cl₂ solution.

^b Measure in CHCl₃ solution.

^c Optical bandgap estimated from the film absorption onset.

^d Highest occupied molecular orbital (HOMO) level measured in CH₂Cl₂.


^e Lowest unoccupied molecular orbital (LUMO) Measured in THF.

^fMeasured in CH₂ClCH₂Cl.

^g Electrochemical bandgaps, calculated from CV.

^h Decomposition temperature, obtained by thermogravimetric analysis (TGA).


Procedures and characterizations of new compounds.



Synthesis of 4-(n-butyl)-4H-benzo[4,5]thieno[3,2-b]thieno[2,3-d]pyrrole (2)

A solution of **1** (5.13 g, 13.7 mmol), sodium *t*-butoxide (10.5 g, 0.11 mol), Pd(dba)₂ (776 mg, 1.37 mmol), and dppf (3.04 g, 5.48 mmol) in toluene (300 mL) was stirred at room temperature for 30 min. To the resulting solution was added *n*-butyl-1-amine (1.62 mL, 16.4 mmol), and the mixture was stirred at 110 °C for 12 h. After the resulting mixture was cooled to room temperature, H₂O was added to the mixture and extracted with ethyl acetate. The combined organic phase was dried over MgSO₄ and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel with hexane as eluent to afford compound **4** as a pale yellow solid (3.6 g, 90%). ¹H NMR (400 MHz, CD₂Cl₂) δ 7.90-7.84 (m, 2H), 7.44-7.40 (m, 1H), 7.31-7.26 (m, 1H), 7.22 (d, *J* = 5.2 Hz, 1H), 7.10 (d, *J* = 5.2 Hz, 1H), 4.53-4.50 (m, 2H), 1.97-1.90 (m, 2H), 1.47-1.38 (m, 2H), 0.95 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (125 MHz, CD₂Cl₂) δ 146.5, 141.8, 137.3, 128.3, 124.9, 124.8, 124.5, 123.4, 119.5, 115.3, 114.4, 111.6, 47.9, 33.6, 20.7, 14.2; IR (KBr) *v* 3100, 3079, 3051, 2956, 2929, 2870, 1590, 1518, 1490, 1469, 1427, 1406, 1385, 1369, 1356, 1300, 1288, 1265, 1236, 1162, 1148, 1133, 1111, 1092, 1077, 1027, 846, 794, 774, 747, 723, 709; M. p.:135-137 °C; HRMS (FAB⁺) m/z calcd for C₁₆H₁₅NS₂: 285.0646, found 285.0641.


4-(isobutyl)-4H-benzo[4,5]*thieno*[3,2-*b*]*thieno*[2,3-*d*]*pyrrole* (3): using **1** (5.13 g, 13.7 mmol), sodium *tert*-butoxide (10.5 g, 0.11 mol), Pd(dba)₂ (776 mg, 1.37 mmol), and dppf (3.04 g, 5.48 mmol), 2-methylpropan-1-amine (isobutylamine) (1.63 mL, 16.4 mmol) and toluene (300 mL) to afford **12** as a pale yellow solid (3.55 g, 90%). ¹H NMR (400 MHz, CD₂Cl₂) δ 7.87-7.84 (m, 2H), 7.44-7.40 (m, 1H), 7.30-7.26 (m, 1H), 7.22 (d, *J* = 5.6 Hz, 1H), 7.09 (d, *J* = 4.8 Hz, 1H), 4.30 (d, *J* = 8.0 Hz, 2H), 2.38-2.31 (m, 1H), 1.00 (d, *J* = 6.4 Hz, 6H); ¹³C NMR (100 MHz, CD₂Cl₂) δ 146.9, 141.9, 137.5, 128.4, 124.9, 124.8, 124.5, 123.4, 119.5, 115.2, 114.5, 111.9, 55.5, 30.9, 20.4; IR (KBr) *v* 3101, 3079, 3050, 2958, 2928, 2869, 1590, 1516, 1490, 1468, 1446, 1426, 1407, 1387, 1356, 1296, 1268, 1252, 1216, 1163, 1135, 1093, 1076, 1058, 1025, 948, 925, 904, 847, 818, 800, 748, 723, 709; M. p.: 109-111 °C; HRMS (FAB⁺) m/z calcd for C₁₆H₁₅NS₂: 285.0646, found 285.0645.



Synthesis of 7-(4-(n-butyl)-4H-benzo[4,5]thieno[3,2-b]thieno[2,3-d]pyrrol-2-yl)benzo[c][1,2,5] thiadiazole-4-carbaldehyde (4)


To a solution of compound 2 (2.85 g, 10 mmol) in THF (100 mL) was added dropwise nbutyllithium (19 mL, 1.6 M in hexane) at -78 °C. After stirring for 1 hour, tributyltin chloride (5.5 mL, 20 mmol) was injected by a syringe and the resulting mixture was warm to room temperature for 12 h, then guenched with H₂O and extracted with diethyl ether. The combined organic phase was washed with H₂O and brine, dried over anhydrous MgSO₄, and concentrated under reduced pressure. A mixture of stannylated 2 (10 mmol), 7-bromobenzo[c][1,2,5]thiadiazole-4carbaldehyde (2.43 g, 10 mmol), and Pd(PPh₃)₂Cl₂ (702 mg, 1.0 mmol) in toluene (100 mL) was stirred and heated at reflux temperature under argon for 5 hours to afford 4 as a purple solid (1.2 g, 36%). ¹H NMR (400 MHz, CD₂Cl₂) δ 10.68 (s, 1H), 8.58 (s, 1H), 8.18 (d, J = 7.2 Hz, 1H), 7.99 (d, J = 7.6 Hz, 1H), 7.92-7.85 (m, 2H), 7.46-7.42 (m, 1H), 7.36-7.32 (m, 1H), 4.60 (t, J = 7.2 Hz, 7.46 (m, 2H))2H), 2.02-1.99 (m, 2H), 1.52-1.46 (m, 2H), 0.99 (t, J = 7.2 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 188.4, 153.9, 152.2, 146.7, 142.5, 139.2, 136.6, 134.3, 133.0, 127.0, 124.7, 124.6, 124.5, 123.9, 122.6, 119.4, 118.3, 114.9, 114.4, 47.4, 33.0, 20.2, 13.8; IR (KBr) v 3051, 2953, 2866, 2837, 1683, 1666, 1589, 1567, 1538, 1522, 1495, 1468, 1428, 1398, 1358, 1327, 1259, 1230, 1203, 1179, 1148, 1133, 1088, 1062, 1011, 931, 891, 856, 839, 810, 803, 775, 750, 723; M. p.: 246-248 °C; HRMS (FAB^+) m/z calcd for C₂₃H₁₇N₃OS₃: 447.0534, found 447.0542.

7-(4-(isobutyl)-4H-benzo[4,5]thieno[3,2-b]thieno[2,3-d]pyrrol-2-yl)benzo[c][1,2,5]thiadiazole-4-carbaldehyde (5): A mixture of stannylated **3** (10.5 mmol), 7-bromobenzo[c][1,2,5]thiadiazole-4-carbaldehyde (2.43 g, 10 mmol), and Pd(PPh₃)₂Cl₂ (702 mg, 1.0 mmol) in toluene (100 mL) was stirred and heated at reflux temperature under argon for 5 hours to afford **5** as a purple solid (2.4 g, 72%). ¹H NMR (400 MHz, CD₂Cl₂) δ 10.69 (s, 1H), 8.57 (s, 1H), 8.20 (d, *J* = 7.6 Hz, 1H), 8.00 (d, *J* = 7.0 Hz, 1H), 7.90-7.86 (m, 2H), 7.46-7.42 (m, 1H), 7.36-7.34 (m, 1H), 4.39 (d, *J* = 7 Hz, 2H), 2.45-2.38 (m, 1H), 1.07 (d, *J* = 6.4 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 188.4, 153.9, 152.2, 147.1, 142.5, 139.4, 136.6, 134.3, 132.9, 127.1, 124.7, 124.6, 124.5, 123.9, 122.7, 119.4, 118.2, 115.2, 114.5, 55.0, 30.3, 20.3; IR (KBr) v 3013, 2963, 1804, 1673, 1537, 1516, 1489, 1465, 1402, 1352, 1338, 1272, 1260, 1231, 1199, 1184, 1155, 1102, 1064, 1052, 1012, 953, 926, 909, 861, 836, 818, 792, 782, 741, 722; M. p.: 296-298 °C; HRMS (FAB⁺) m/z calcd for C₂₃H₁₇N₃OS₃: 447.0534, found 447.0530.



Synthesis of nBuBTDC

A mixture of **4** (250 mg, 0.56 mmol), malononitrile (55 mg, 0.84 mmol) and 3 drops of triethylamine was stirred at room temperature in CHCl₃ (10 mL) under N₂ for 20 minutes. The reaction mixture was directly precipitated with EA. The crude product was washed with CH₂Cl₂, EA and pentane to afford **nBuBTDC** as a blue-violet solid (250 mg, 90 %). ¹H NMR (400 MHz, CD₂ClCD₂Cl) δ 8.73 (s, 1H), 8.71 (d, *J* = 8.4 Hz, 1H), 8.51 (s, 1H), 7.98 (d, *J* = 8.0 Hz, 1H), 7.91-7.89 (m, 2H), 7.49-7.47 (m, 1H), 7.41-7.37 (m, 1H), 4.58 (brs, 2H), 2.05-1.99 (m, 2H), 1.52-1.47 (m, 2H), 1.00 (t, *J* = 7.2 Hz, 3H); ¹³C NMR could not be recorded due to the low solubility of **nBuBTDC**. IR (KBr) *v* 3094, 3050, 2956, 2217, 1676, 1571, 1523, 1429, 1415, 1337, 1270, 1230, 1160, 1079, 1062, 1040, 1027, 934, 895, 862, 848, 831, 798, 747, 720; M. p.: 314 °C (DSC); HRMS (MALDI) m/z calcd for C₂₆H₁₇N₅S₃: 495.0646, found 495.0660.



Synthesis of iBuBTDC

A mixture of **5** (250 mg, 0.56 mmol), malononitrile (55 mg, 0.84 mmol) and 3 drops of triethylamine was stirred at room temperature in CHCl₃ (10 mL) under N₂ for 20 minutes. The reaction mixture was directly poured into methanol. The precipitate was purified by flash column with CHCl₃ as eluent to afford **iBuBTDC** as a blue-violet solid (250 mg, 90%). ¹H NMR (400 MHz, CDCl₃) δ 8.71 (d, *J* = 6.8 Hz, 1H), 8.70 (s, 1H), 8.53 (s, 1H), 7.93 (d, *J* = 8.4 Hz, 1H), 7.87-7.83 (m, 2H), 7.44-7.42 (m, 1H), 7.37-7.35 (m, 1H), 4.35 (d, *J* = 7.2 Hz, 2H), 2.42-2.38 (m, 1H), 1.08 (d, *J* = 6.4 Hz, 6H); ¹³C NMR could not be recorded due to the low solubility of **iBuBTDC**. IR (KBr) *v* 3093, 2961, 2218, 1849, 1732, 1644, 1571, 1536, 1519, 1463, 1428, 1399, 1337, 1271, 1230, 1165, 1102, 1080, 1064, 1040, 1027, 932, 888, 860, 845, 827, 793, 748, 719, 706; M. p.: 316 °C (DSC); HRMS (MALDI) m/z calcd for C₂₆H₁₇N₅S₃: 495.0646, found 495.0620.

[1] X. Che, C.-L. Chung, X. Liu, S.-H. Chou, Y.-H. Liu, K.-T. Wong, S. R. Forrest, Advanced Materials 2016, 28, 8248.